2. Academic Validation
  3. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

  • Cell Rep Med. 2023 Jan 10;100911. doi: 10.1016/j.xcrm.2022.100911.
Han-Min Wang 1,  Chan-Yuan Zhang 2,  Kai-Cheng Peng 3,  Ze-Xin Chen 4,  Jun-Wei Su 1,  Yu-Fa Li 1,  Wen-Feng Li 1,  Qing-Yun Gao 1,  Shi-Ling Zhang 2,  Yu-Qing Chen 3,  Qing Zhou 1,  Cong Xu 4,  Chong-Rui Xu 1,  Zhen Wang 1,  Jian Su 1,  Hong-Hong Yan 1,  Xu-Chao Zhang 1,  Hua-Jun Chen 5,  Yi-Long Wu 6,  Jin-Ji Yang 7
Affiliations

Affiliations

  • 1 Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
  • 2 Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China; The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.
  • 3 Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China; School of Medicine, South China University of Technology, Guangzhou 510006, China.
  • 4 Guangdong Research Center of Organoid Engineering and Technology, Guangzhou 510530, China.
  • 5 Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China. Electronic address: chenhuajun@gdph.org.cn.
  • 6 Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China. Electronic address: syylwu@live.cn.
  • 7 Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China; The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China; School of Medicine, South China University of Technology, Guangzhou 510006, China. Electronic address: yangjinji@gdph.org.cn.
PMID: 36657446 DOI: 10.1016/j.xcrm.2022.100911
Abstract

Predicting the clinical response to chemotherapeutic or targeted treatment in patients with locally advanced or metastatic lung Cancer requires an accurate and affordable tool. Tumor organoids are a potential approach in precision medicine for predicting the clinical response to treatment. However, their clinical application in lung Cancer has rarely been reported because of the difficulty in generating pure tumor organoids. In this study, we have generated 214 Cancer organoids from 107 patients, of which 212 are lung Cancer organoids (LCOs), primarily derived from malignant serous effusions. LCO-based drug sensitivity tests (LCO-DSTs) for chemotherapy and targeted therapy have been performed in a real-world study to predict the clinical response to the respective treatment. LCO-DSTs accurately predict the clinical response to treatment in this cohort of patients with advanced lung Cancer. In conclusion, LCO-DST is a promising precision medicine tool in treating of advanced lung Cancer.

Keywords

chemotherapy; drug sensitivity test; lung cancer; patient-derived organoid; personalized medicine; real-world study; targeted therapy.

Figures
Products